Non-statin LDL-lowering therapies reduce cardiovascular events proportionally to the LDL reduction achieved
10 events · 5 assessments · 4 decisions
Reassessed (status unchanged) and brought argument evaluations current
Trigger: the supporting subclaim "Adding ezetimibe to statin therapy reduces cardiovascular events" moved to verified (0.82) on IMPROVE-IT. This was the last of the three support pillars not yet formally assessed, so the change is confirmatory in the "for" direction and was already anticipated. Status holds at supported: the three supporting premises (statin benchmark, PCSK9 inhibitors, ezetimibe) are now all verified and give a consistent per-unit slope for LDL-receptor-mediated agents, but the canonical wording quantifies over all non-statin LDL-lowering therapies without restriction, and the verified counterexample subclaim falsifies that strict universal reading. Nudged confidence to 0.88 and recorded credence ~0.85; refreshed the reader-facing prose and reasoning trace. The substantive gap this pass was that both named arguments carried stale evaluations, one still asserting ezetimibe was "not yet formally assessed"; both re-evaluated against current premise standing (both holds_with_caveats). Importance left at 0.6 (major, moderately live cardiology thesis). No dependent notification: status and direction unchanged, purely confirmatory.
Reassessed: still Supported
verdict confidence 0.88 · credence 0.85
Reassessed: still Supported
verdict confidence 0.86 → 0.88 · credence 0.86
Reassessed
Triggered by the contradicting subclaim "Some interventions that lower LDL cholesterol failed to reduce cardiovascular events" moving to VERIFIED (0.95). Judged the change confirmatory, not status-moving: the subclaim is a neutral existence statement whose own reasoning notes the failures are explained by off-target harms (torcetrapib) or insufficient on-target lowering (niacin, earlier CETP inhibitors), with anacetrapib later reducing events. This confirms, rather than undermines, the existing basis for holding the claim at "supported" (literal all-therapies scope falsified by counterexamples) rather than "verified" (receptor-mediated proportionality well backed by IMPROVE-IT, FOURIER, ODYSSEY OUTCOMES, and the statin benchmark). Ran one external evidence check confirming a broadly consistent ~0.85 RR per 1 mmol/L across statins/ezetimibe/PCSK9, with absolute benefit scaling to baseline risk. Held status supported, nudged confidence 0.85->0.86, credence held 0.85. Filled the two missing named-argument evaluations (both holds_with_caveats) and brought the reasoning current with the anacetrapib reconciliation. Confirmed importance at 0.6 (Major) with contestation 0.4. No canonical-form change: narrowing to "receptor-mediated" would be a different claim (individuation), left to the broad debated wording. No dependent notification: status unchanged and the change is not material upstream.
Reassessed: still Supported
verdict confidence 0.85 → 0.86 · credence 0.85
Reassessed
Triggered by the PCSK9-inhibitor subclaim moving to VERIFIED (FOURIER, ODYSSEY OUTCOMES). The change is confirmatory and strengthens the "for" argument (which also rests on the ezetimibe subclaim and the verified statin-benchmark subclaim). It does not flip the status: the reason this claim sits at "supported" rather than "verified" is the scope ambiguity in the literal wording (all non-statin LDL-lowering therapies), which is bounded by the niacin/CETP counterexamples captured in the contradicting subclaim, and strengthening PCSK9 does not resolve that. Kept status supported; nudged confidence 0.83 to 0.85 to reflect that one supporting mechanism is now formally verified; held credence at 0.85. No structural change: the existing decomposition (two supporting mechanisms, statin benchmark, and the failed-intervention counterexample) still captures what the claim turns on. Set importance to 0.6 (major) with contestation 0.3: consequential for lipid-lowering practice but the receptor-mediated core is now largely settled. No dependent notification: my assessment did not materially change (status and credence essentially stable), so downstream stewards need no re-judgment.
Reassessed: still Supported
verdict confidence 0.83 → 0.85 · credence 0.85
Structured and assessed
First pass. Decomposed into two arguments. For: created subclaims on ezetimibe (IMPROVE-IT) and PCSK9 inhibitors (FOURIER/ODYSSEY), and linked the existing statin benchmark claim (d81f89e3) as the reference proportionality slope. Against: created a contradicts subclaim capturing LDL-lowering interventions (niacin, CETP inhibitors) that failed to show proportional benefit. Matcher confirmed the ezetimibe, PCSK9, and counter subclaims were novel; the proposed "meta-analysis shows non-statin proportionality matches statins" framing matched this claim itself, so it was not minted (used as evidence in reasoning instead). Verified external evidence via web search: Silverman 2016 JAMA meta-analysis (similar RR per mmol/L across statin/non-statin receptor-mediated therapies), IMPROVE-IT, CLEAR Outcomes bempedoic acid. Set importance 0.5 (major clinical claim, moderate contestation), contestation 0.35. Assessed SUPPORTED (conf 0.83, credence 0.85): well-established for LDL-receptor-mediated therapies, but literal "all non-statin therapies" reading bounded by niacin/CETP counterexamples, hence supported not verified. This claim already supports the verified broad proportionality claim 97aca08f.
Assessed Supported
verdict confidence 0.83 · credence 0.85
The evidence favours this claim for the therapies that lower LDL cholesterol by increasing LDL-receptor activity, and this is the mainstream view in preventive cardiology. Randomized outcome trials of three distinct non-statin mechanisms point the same way: ezetimibe added to a statin (IMPROVE-IT) produced further LDL lowering and a matching reduction in cardiovascular events; PCSK9 inhibitors on top of statins (FOURIER, ODYSSEY OUTCOMES) achieved large LDL reductions with event reductions tracking the LDL change; and bempedoic acid in statin-intolerant patients (CLEAR Outcomes) reduced major events by about the amount its LDL lowering predicts. A meta-analysis pooling statin and non-statin trials found the relative risk of major vascular events falls by roughly a fifth per 1 mmol/L of LDL reduction regardless of which of these agents achieves it, the same per-unit slope established for statins. The important qualification is mechanistic rather than a genuine rival account. Several interventions that lower LDL by other routes, notably niacin and several CETP inhibitors, did not deliver the expected event reduction. These are generally explained by off-target harms or by the drugs acting largely outside the LDL-receptor pathway, so they bound the claim rather than overturn it: proportionality is robust for therapies that reduce circulating LDL particle number, and should not be assumed automatically for any compound that happens to lower measured LDL. Read as a statement about LDL-receptor-mediated LDL lowering, the proportional relationship is well supported; read as a claim about every non-statin agent that lowers LDL, it is too strong. What would sharpen the assessment further is longer-term and mechanism-diverse outcome data and formal tests of whether the per-unit slope is statistically indistinguishable from the statin benchmark.
Claim entered the graph